Cue Biopharma

This first-in-human study tested a new drug called CUE-101, designed to activate the immune system to fight cancers caused by HPV. It was given to about 80 adults with advanced head and neck cancer, either alone for patients who had already tried other treatments, or combined wit…

This early-stage study tested a new immunotherapy drug called CUE-102 in patients with advanced cancers that had returned or spread after standard treatments. The main goals were to find a safe dose and see how the body processes the drug. It involved 42 adults with specific type…